The new drug, Dalvance, is part of the FDA's Generating Antibiotic Incentives Now program, which aims at stopping antibiotic resistant bacteria like MRSA. It also qualified for the Fast Track review ...
The story of MRSA begins just four years after methicillin entered medical practice in 1959. The bacteria had already developed resistance to the new antibiotic, demonstrating the remarkable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results